InsidersTradesSigma
Glenmark Pharmaceuticals Limited: insider trades · India · SEBI (PIT + SAST)
SEBI:glenmark-pharmaceuticals-limitedIN·SEBI (PIT + SAST)Mcap 434.6Bn€
Discover the full directors' dealings record of Glenmark Pharmaceuticals Limited, a listed issuer based in India. Shares are listed on IN IN, under the oversight of SEBI (PIT + SAST). Market capitalisation: €434.6bn. The latest transaction was disclosed on 22 September 2023 — Sale. Among the most active insiders: Glenn Mario Saldanha. Every trade is accessible without an account.
13
Insider Decl.
0
Thresholds
€203,926
7 ops.
Buy Volume
€27,554
6 ops.
Sell Volume
Financial data
FY ended March 2025 · cache
2339.90 €
Income statement
Revenue131.46 Bn€
Gross profit83.88 Bn€64% margin
Net income10.47 Bn€8.0% margin
Balance sheet & cash
Market cap434.58 Bn€
Total debt24.73 Bn€
Free Cash Flow−15.77 Bn€
Last declaration on 22 September 2023
Declarations13 total
Executives●Sale0SEBI
€9,6181,000 shares@ €9.6182
Equity Shares
SEBI:7c43f029fcf65d701002d87cbc38f4b76c05691e·
Executives●Sale0SEBI
€4,804500 shares@ €9.6072
Equity Shares
SEBI:e66100d169abd1b49336835c9bcfd5956cdd6833·
Executives●Sale0SEBI
€9,6181,000 shares@ €9.6182
Equity Shares
SEBI:4735f3b198350556570238ed4d2ffa4d36737a5f·
Executives●Purchase0SEBI
€1,463250 shares@ €5.8529
Equity Shares
SEBI:a283ff59f1d01e5f26fe4c410f3339b8dd4e629e·
Ideal exit: 20 Aug 2022 (T+270)
Executives●Sale0SEBI
€3,514559 shares@ €6.2857
Equity Shares
SEBI:ad6a757c300c502fcdefcf162081d13e883d157f·
Executives●Sale0SEBI
010,000 shares
Equity Shares
SEBI:a1e94610183e8e27382d484204aff805092b4751·
Executives●Purchase0SEBI
020,000 shares
Equity Shares
SEBI:e06c089566a41c4b5ee160b60fbae8e1e10c0e7b·
Ideal exit: 24 Jun 2022 (T+270)
Executives●Sale0SEBI
010,000 shares
Equity Shares
SEBI:1511c0d568f366fa2576ec8a989296183f4d31d3·
Executives●Purchase0SEBI
€57,9379,800 shares@ €5.912
Equity Shares
SEBI:32da8d7c912f1d4d9db504832ae09f596a698347·
Ideal exit: 21 Jun 2022 (T+270)
Executives●Purchase0SEBI
€11,5721,950 shares@ €5.9344
Equity Shares
SEBI:da3603681fcec6d45c53b1c6d36c6d3f53bdf9e4·
Ideal exit: 19 Jun 2022 (T+270)
Executives●Purchase7SEBI
€56,3857,800 shares@ €7.22880.0000% mcap42.4% of flow
Equity Shares
SEBI:fe9844636b32f99c393cfd6c43b8d98c8ab54355·
Ideal exit: 20 Mar 2022 (T+270)
Executives●Purchase5SEBI
€20,2352,800 shares@ €7.22670.0000% mcap15.2% of flow
Equity Shares
SEBI:8de2ea524f0611f5960938f5b20074c58d0281b6·
Ideal exit: 19 Mar 2022 (T+270)
Executives●Purchase7SEBI
€56,3347,870 shares@ €7.15810.0000% mcap42.4% of flow
Equity Shares
SEBI:cbe4bc773724e8e0f53f03e1d6508c57011868b5·
Ideal exit: 6 Mar 2022 (T+270)
13 of 13 declarations